Trial Information
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
